CMENEUTRAL

Return on Equity (ROE)

15.9%

Updated 102h ago

Sector Performance

57th percentile

CME

15.9%

Sector Median

13.8%

Sector Avg

31.4%

📊

Deep Analysis

CME’s current Return on Equity (ROE) of 15.9% measures how much profit the company generates from each dollar of shareholders’ equity — a higher ROE generally indicates more efficient use of invested capital.

This figure sits above the sector median of 13.8%, placing CME in the 57th percentile among its peers, meaning it outperforms a slight majority of comparable companies. No trend data is available: both the year-over-year and quarter-over-quarter changes are listed as not applicable, and no historical values beyond the current 15.9% are provided. The combination of a ROE above the sector median with an unknown trend offers a mixed picture — the current level suggests reasonable profitability relative to peers, but the absence of trend information makes it impossible to assess whether performance is improving or weakening. This metric aligns with the overall NEUTRAL verdict because the ROE is modestly above average but not exceptional, and the lack of directional data prevents a stronger positive or negative conclusion.

Frequently Asked Questions

What does the Return on Equity (ROE) tell investors about CME?

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.

How is the Return on Equity (ROE) calculated?

Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.

Who are CME's closest peers by Return on Equity (ROE)?

The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).

The Formula

Net Income / Shareholders' Equity

Why It Matters

ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.